Dendritic cell-based immunotherapy for multiple myeloma -- review.
- Author:
Xue-Jun ZHU
1
;
Long HE
;
Xue-Mei SUN
Author Information
1. Department of Hematology, Traditional Chinese Medicine Hospital of Jiangsu Province, Nanjing, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Cancer Vaccines;
immunology;
therapeutic use;
Dendritic Cells;
immunology;
Humans;
Immunotherapy;
Multiple Myeloma;
therapy
- From:
Journal of Experimental Hematology
2009;17(3):821-825
- CountryChina
- Language:Chinese
-
Abstract:
Patients with multiple myeloma (MM) have increased constantly in recent years, but treatment for patients with MM is currently unsatisfactory and it is necessary to develop new complementary therapies. Dendritic cells (DCs) are specialized antigen-presenting cells capable of initiating and regulating immune responses. Vaccination with tumor antigen-pulsed DCs has shown to be safe and possesses therapeutic effect against many tumors. In this review, the various types of MM-associated antigens and clinical trials on DC-based immunotherapy in MM are summarized, the development of DC immunotherapy for MM patients in future trials is discussed.
